General Announcement::Glenmark Pharmaceuticals and Helsinn Group enter into an exclusive licensing agreement

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
04-Apr-2018 16:59:24
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals and Helsinn Group enter into an exclusive licensing agreement
Announcement Reference
SG180404OTHRRPB6
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
04/04/2018 14:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals and Helsinn Group enter into an exclusive licensing agreement for launch of AKYNZEO in India and Nepal

Dear Sir/Madam,

With reference to the above subject mentioned above, kindly find attached media release which is self-explanatory.

Requesting you to kindly take the same on record.

Attachments

SGX_040418.pdf
Total size =595K